Smith & Nephew plc: Q2 and H1 2024 Financial Summary
Business Context and Reporting Period
This Form 6-K filing reports the Second Quarter and First Half 2024 results for Smith & Nephew plc, a global medical technology company. The reporting period covers the six months ended June 29, 2024. The company operates three primary business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The results reflect the ongoing execution of the "12-Point Plan" aimed at operational transformation, margin expansion, and cash flow improvement.
Key Financial Metrics
| Metric | H1 2024 | H1 2023 | Change |
|---|---|---|---|
| Revenue | $2,827 million | $2,734 million | +3.4% (Reported) / +4.3% (Underlying) |
| Operating Profit | $328 million | $275 million | +19.5% |
| Trading Profit | $471 million | $417 million | +12.8% |
| Trading Profit Margin | 16.7% | 15.3% | +140 bps |
| EPS (Basic) | 24.5 cents | 19.7 cents | +24.6% |
| EPSA (Adjusted) | 37.6 cents | 34.9 cents | +7.7% |
| Cash from Operations | $368 million | $215 million | +71.2% |
| Trading Cash Flow | $284 million | $110 million | +158.2% |
| Net Debt | $3,086 million | $2,776 million | Increased |
| Leverage Ratio | 2.2x | 2.1x | Increased |
Material Changes vs. Prior Period
- Revenue Growth: Underlying revenue grew 4.3% in H1 2024, driven by positive performance across all three business units. Reported growth was 3.4%, impacted by a -90bps foreign exchange headwind.
- Profitability Expansion: Trading profit margin expanded to 16.7%, reaching the top of the guided range. This was driven by operating leverage and productivity savings from the 12-Point Plan, offsetting inflation and China Volume-Based Procurement (VBP) headwinds.
- Cash Flow Improvement: Trading cash flow conversion improved significantly to 60% (up from 26% in H1 2023), resulting in a trading cash flow of $284 million. Free cash flow turned positive at $39 million, compared to an outflow of $82 million in the prior year.
- Segment Performance:
- Orthopaedics: Revenue up 5.1% underlying. Strong growth in Trauma & Extremities and Other Reconstruction (robotics). US Hip and Knee Implants showed signs of recovery but remain a focus for improvement.
- Sports Medicine & ENT: Revenue up 6.5% underlying. Growth was strong outside of China, where VBP implementation created a headwind.
- Advanced Wound Management: Revenue up 0.7% underlying, returning to growth with contributions from all segments.
- Debt Position: Net debt increased to $3,086 million, primarily due to the $180 million acquisition of CartiHeal and the payment of the final 2023 dividend ($202 million), partially offset by free cash flow generation.
Guidance, Outlook, and Risks
- Full Year Guidance: Unchanged. The company expects underlying revenue growth of 5.0% to 6.0% (4.4% to 5.4% reported) and a trading profit margin of at least 18.0%.
- Outlook: Management expects stronger performance in the second half of 2024, particularly in US Hip and Knee Implants. The trading profit margin is expected to be higher in H2 than H1.
- Capital Allocation: Updated framework prioritizes organic growth and acquisitions, followed by maintaining an optimal balance sheet (target leverage ~2.0x) and a progressive dividend policy (target payout 35-40% of EPSA from 2025).
- Risks and Contingencies:
- China VBP: Continued headwind in Sports Medicine Joint Repair, estimated at -70bps impact on margin for the full year.
- Legal: Ongoing metal-on-metal hip claims; a $12 million provision decrease was recorded in H1 2024.
- Subsequent Event: Announcement of the closure of the Warwick manufacturing site, expected to incur approximately $75 million in losses (including $60 million goodwill impairment) in H2 2024.
- Regulatory: Costs associated with EU Medical Device Regulation implementation.
Key Facts for Investor Verification
- Verify the sustainability of the 60% trading cash flow conversion rate and the path to the historical 85% target.
- Monitor the turnaround progress in US Hip and Knee Implants, which represents ~15% of the Group and was previously underperforming.
- Assess the impact of the Warwick site closure ($75m loss) on H2 2024 results and goodwill impairment charges.
- Track the integration and revenue contribution of the CartiHeal acquisition ($231m consideration) in the Sports Medicine segment.
- Confirm the ability to achieve the 18.0% trading profit margin target given persistent inflation and FX headwinds.